Investor Presentaiton

Allergy Therapy Business Allergen Immunotherapy (AIT) Market Size Industry Overview Business Overview Products Global AIT market stands at US$1.8bn and is expected to grow at CAGR of 8.9% to reach US$2.8bn by 2022 Major growth drivers include the increased prevalence of allergic diseases, reduced time to drug approval processes and increased pharmaceutical R&D spending & biotechnology investment Venom immunotherapy is considered effective for the prevention of potential allergic reactions to hymenoptera stings ➤ Jubilant HollisterStier Allergy is the sole supplier for venom immunotherapy in the US (US$bn) 1.4 CAGR 12-17:3.8% CAGR 2017-22: 8.9% 2.6 2.8 1.8 1.7 2.0 2.1 2.3 0.5 0.4 0.4 0.3 0.3 1.4 1.6 1.6 0.2 0.2 0.2 0.2 0.2 0.3 1.2 1.3 1.4 1.5 1.5 1.7 1.8 1.2 5 6 ■Global Ex-US North America 1.9 2.1 2.3 2021F Jubilant has become the number 2 player in the allergenic extract market in the US Offers a range of different allergenic extracts and standard allergy vaccine mixtures as well as insect venom products for the treatment of allergies to insect stings Traditionally focused on North America as the key market, where significant brand loyalty is generated in respect of the "HollisterStier" brand Dedicated sales force in the US and distributors in Europe, Canada and South Korea Products are sold primarily in bulk and then mixed in the office/clinic environment USFDA approved manufacturing facilities at Spokane facility Product range includes 200+ different allergenic extracts, six insect venom products and exclusive skin diagnostic testing devices Currently the sole producer and supplier of venom products for the treatment of allergies in the US ➤ Expect to benefit from barriers to entry as biotechnology products with grandfather status; new products require an NDA Leverage Existing Capabilities Drive growth and profitability through our strong customer commitment to be partner-of-choice in US allergy market Enhance US Footprint & Portfolio Strategy Launch new, differentiated products and expand capacities in particular in venom and extract products Improve existing processes and supply reliability Expand Target Markets & Portfolio Explore adjacencies or vertical integration such as supplier & distribution agreements or diagnostic testing services Entered into partnerships to further deepen the penetration in Canada and Europe 2022F Source: Frost & Sullivan - Independent Market Research on the Radiopharmaceutical Industry, US Radiopharmacy Chain, US Contract Manufacturing Organisation Industry, US Allergy Immuno Therapy Industry and the Global and US Generic Pharmaceutical Industry JUBILANT LIFESCIENCES

View entire presentation